GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery
NCT ID: NCT00878163
Last Updated: 2025-09-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE1
55 participants
INTERVENTIONAL
2009-03-31
2026-03-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
NCT01064622
Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery
NCT01660971
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery
NCT01013649
Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer
NCT00810719
Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors
NCT00033241
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To determine the maximum tolerated dose of erlotinib hydrochloride and Hedgehog antagonist GDC-0449 with or without gemcitabine hydrochloride in patients with unresectable solid tumors.
SECONDARY OBJECTIVES:
I. To describe the adverse events profile associated with these treatment regimens.
II. To describe the responses in patients treated with these regimens. III. To assess the effect of erlotinib hydrochloride and Hedgehog antagonist GDC-0449 on selected biomarkers in circulating tumor cells and tumor biopsy samples from patients with metastatic pancreatic cancer.
IV. To assess the effect of erlotinib hydrochloride and Hedgehog antagonist GDC-0449 on fludeoxyglucose F 18 positron emission tomography imaging in patients with metastatic pancreatic cancer.
V. To study the association between clinical (toxicity and/or tumor response or activity) and biologic (pharmacodynamic) results associated with erlotinib hydrochloride and Hedgehog antagonist GDC-0449 in patients with metastatic pancreatic cancer.
OUTLINE: This is a dose-escalation study of erlotinib hydrochloride.
Patients receive Hedgehog antagonist GDC-0449 orally (PO) once daily (QD) and erlotinib hydrochloride PO QD on days 1-28. Some patients also receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients treated at the maximum tolerated dose undergo fludeoxyglucose F 18 positron emission tomography at baseline and on day 28. These patients also undergo tumor tissue and blood sample collection at baseline and periodically during study for correlative laboratory studies. Samples are analyzed for tyrosine phosphorylated or total MAP-K, EGFR, AKT, and other potential biomarkers of activity/response and for levels of genes transcriptionally activated (e.g., BCL-2, GLI, BFL-1/A1, 4-1BB, PTC1) by immunofluorescence, IHC, and quantitative-PCR.
After completion of study therapy, patients are followed at 3 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment (vismodegib, erlotinib hydrochloride, gemcitabine)
Patients receive Hedgehog antagonist GDC-0449 PO QD and erlotinib hydrochloride PO QD on days 1-28. Some patients also receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Diagnostic Laboratory Biomarker Analysis
Correlative studies
Erlotinib Hydrochloride
Given PO
Gemcitabine Hydrochloride
Given IV
Vismodegib
Given PO
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Diagnostic Laboratory Biomarker Analysis
Correlative studies
Erlotinib Hydrochloride
Given PO
Gemcitabine Hydrochloride
Given IV
Vismodegib
Given PO
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Metastatic adenocarcinoma of the pancreas amenable to biopsies (cohort II MTD only)
* Absolute neutrophil count (ANC) \>= 1,500/μL
* Platelets \>= 100,000/μL
* Total bilirubin =\< upper limit of normal (ULN)
* Aspartate aminotransferase (AST) =\< 3 times upper limit of normal (ULN)
* Creatinine =\< 1.5 times ULN
* Hemoglobin \>= 9.0 g/dL
* International Normalized Ratio (INR) within normal limits (for patients treated at the MTD)
* Ability to provide informed consent
* Willingness to return to Mayo Clinic for follow up
* Life expectancy \>= 12 weeks
* Willingness to provide the biologic specimens as required by the protocol
* Negative serum pregnancy test done =\< 7 days prior to registration
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2
* Able to swallow or have medication administered through a G-tube and absorb the medication
* Participant agrees to use an acceptable form of contraception; acceptable forms of contraception:
* Latex condom (always used with spermicide)
* Diaphragm (always used with spermicide)
* Cervical cap (always used with spermicide)
Acceptable forms of secondary contraceptions, when used along with a barrier method:
* Hormonal contraception methods, including pills, patches, rings, or injections except progestin-only containing pills (i.e. "Mini-pill")
* Tubal ligation
* Partner's vasectomy
* Intrauterine device (IUD) (non-progesterone T)
* Vaginal sponge (containing spermicide)
* 100% commitment to abstinence
Unacceptable forms of contraception for women of childbearing potential:
* Oral contraception containing progestins only
* IUD progesterone T
* Female condom
* Natural family planning (rhythm method) or breastfeeding
* Fertility awareness
* Withdrawal
* Cervical shield
* Willing to abstain from smoking
* Willing to complete a daily pill diary
Exclusion Criteria
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* Any of the following prior therapies:
* Chemotherapy =\< 4 weeks prior to registration
* Mitomycin C/nitrosoureas =\< 6 weeks prior to registration
* Immunotherapy =\< 4 weeks prior to registration
* Biologic therapy =\< 4 weeks prior to registration
* Radiation therapy =\< 4 weeks prior to registration
* Radiation to \> 25% of bone marrow
* Failure to fully recover from acute, reversible effects of prior therapy regardless of interval since last treatment
* New York Heart Association classification III or IV
* Seizure disorder
* Central nervous system (CNS) metastases if not stable for at least 2-3 months based on imaging, clinical assessment, and use of steroids, or seizure disorder
* Pregnant women
* Nursing women
* Men or women of childbearing potential who are unwilling to employ adequate contraception until 12 months after last study drug dose
* Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration \[FDA\]-approved indication and in the context of a research investigation)
* Current therapy with a CYP3A4 inhibitor or inducer
* Immunocompromised patients (other than that related to the use of corticosteroids) including patients receiving highly active antiretroviral therapy (HAART) treatment
* Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
* Active other malignancy, excepting non-melanotic skin cancer or carcinoma-in-situ of the cervix; if there is a history of prior malignancy, they must not be receiving other specific treatment (other than hormonal therapy) for their cancer
* History of myocardial infarction =\< 6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias
* Abnormalities of the cornea based on history (e.g., dry eye syndrome, Sjogren's syndrome), congenital abnormality (e.g., Fuch's dystrophy), abnormal slit-lamp examination using a vital dye (e.g., fluorescein, Bengal Rose), and/or an abnormal corneal sensitivity test (Schirmer test or similar tear production test)
* More than 2 prior chemotherapy regimens for the current metastatic malignancy; full dose chemotherapy used in conjunction with concurrent radiation therapy will be included as prior therapy; Note: prior hormonal therapy (e.g. leuprolide, aromatase inhibitors, tamoxifen) will be allowed and not included as a prior chemotherapy
* Previous therapy with a hedgehog inhibitor
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Charles Erlichman
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic in Arizona
Scottsdale, Arizona, United States
Mayo Clinic in Florida
Jacksonville, Florida, United States
Orlando Health Cancer Institute
Orlando, Florida, United States
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2011-01400
Identifier Type: REGISTRY
Identifier Source: secondary_id
CDR0000638302
Identifier Type: -
Identifier Source: secondary_id
MAYO-MC0811
Identifier Type: -
Identifier Source: secondary_id
MC0811
Identifier Type: OTHER
Identifier Source: secondary_id
8231
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2011-01400
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.